

DOCKET NO.: 296551US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

GROUP: 1639

Bertrand TAVITIAN, et al.

SERIAL NO: 10/593,256

EXAMINER: WESSENDORF, TERESA D

FILED: September 18, 2006

FOR: APTAMERS SELECTED FROM LIVE TUMOR CELLS AND THE USE
THEREOF

RESTRICTION RESPONSE

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

In response to the Restriction Requirement dated June 25, 2010, Applicants elect, with traverse, Group I, Claims 1-6, 37 and 45, (drawn to a method for identifying ligands or aptamers specific for a membrane receptor protein-tyrosine kinase (RPTK), expressed in an activated or nonactivated form, by cells, using a mixture of nucleic acids), for examination.

Applicants also provisionally elect, for examination purposes only, the following species:

- 1) aptamers (at least claim 1 readable thereon);
- 2) biological activity: reversion of the phenotype associated with activation of the RPTK (at least claim 6 readable thereon);
- 3) receptor protein-tyrosine kinase: RET receptor (at least claim 8 readable thereon).

Remarks/Arguments begin on page 2 of this paper.